Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA.
Sydney Children's Hospital, Randwick, NSW 2031, Australia; School of Women's and Children's Health, UNSW Medicine, The University of New South Wales, NSW 2031, Australia; Genetics of Learning Disability Service, Waratah, NSW 2298, Australia.
Cell. 2018 Feb 22;172(5):924-936.e11. doi: 10.1016/j.cell.2018.02.006.
Certain mutations can cause proteins to accumulate in neurons, leading to neurodegeneration. We recently showed, however, that upregulation of a wild-type protein, Ataxin1, caused by haploinsufficiency of its repressor, the RNA-binding protein Pumilio1 (PUM1), also causes neurodegeneration in mice. We therefore searched for human patients with PUM1 mutations. We identified eleven individuals with either PUM1 deletions or de novo missense variants who suffer a developmental syndrome (Pumilio1-associated developmental disability, ataxia, and seizure; PADDAS). We also identified a milder missense mutation in a family with adult-onset ataxia with incomplete penetrance (Pumilio1-related cerebellar ataxia, PRCA). Studies in patient-derived cells revealed that the missense mutations reduced PUM1 protein levels by ∼25% in the adult-onset cases and by ∼50% in the infantile-onset cases; levels of known PUM1 targets increased accordingly. Changes in protein levels thus track with phenotypic severity, and identifying posttranscriptional modulators of protein expression should identify new candidate disease genes.
某些突变会导致蛋白质在神经元中积累,从而导致神经退行性变。然而,我们最近表明,其抑制剂 RNA 结合蛋白 Pumilio1(PUM1)的杂合不足导致野生型蛋白 Ataxin1 的上调,也会导致小鼠的神经退行性变。因此,我们寻找了具有 PUM1 突变的人类患者。我们鉴定了十一名 PUM1 缺失或从头错义变异的个体,他们患有发育综合征(Pumilio1 相关发育障碍、共济失调和癫痫;PADDAS)。我们还在一个具有成年发病和不完全外显率的家族中鉴定到一个轻度错义突变(Pumilio1 相关小脑共济失调,PRCA)。在患者来源的细胞中的研究表明,错义突变使成年发病病例中的 PUM1 蛋白水平降低了约 25%,使婴儿发病病例中的 PUM1 蛋白水平降低了约 50%;相应地,已知的 PUM1 靶标水平增加。因此,蛋白质水平的变化与表型严重程度相关,鉴定蛋白质表达的转录后调节剂应该可以识别新的候选疾病基因。